{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:10:40Z","timestamp":1794060640254,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"am","delay-in-days":392,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.02.049","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:29:29Z","timestamp":1678494569000},"page":"2376-2381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3491-9985","authenticated-orcid":false,"given":"Patrick A.","family":"Clay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-9520","authenticated-orcid":false,"given":"Lauri E.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatus U.","family":"Ekwueme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-828X","authenticated-orcid":false,"given":"Mona","family":"Saraiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrell W.","family":"Chesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.02.049_b0005","doi-asserted-by":"crossref","first-page":"724","DOI":"10.15585\/mmwr.mm6833a3","article-title":"Human papillomavirus-attributable cancers \u2014 United States, 2012\u20132016","volume":"68","author":"Senkomago","year":"2019","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.02.049_b0010","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1016\/j.vaccine.2012.07.056","article-title":"Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States","volume":"30","author":"Chesson","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.049_b0015","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-1968","article-title":"Prevalence of HPV after introduction of the vaccination program in the United States","volume":"137","author":"Markowitz","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.02.049_b0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in Human Papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003\u20132010","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.049_b0025","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/infdis\/jix244","article-title":"Prevalence of human papillomavirus among females after vaccine introduction\u2014National Health and Nutrition Examination Survey, United States, 2003\u20132014","volume":"216","author":"Oliver","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.049_b0030","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/cid\/ciab171","article-title":"Significant declines in juvenile-onset recurrent respiratory papillomatosis following human papillomavirus (HPV) vaccine introduction in the United States","volume":"73","author":"Meites","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.049_b0035","doi-asserted-by":"crossref","DOI":"10.7326\/M21-3798","article-title":"Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018","author":"Rosenblum","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2023.02.049_b0040","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2105\/AJPH.2012.301182","article-title":"Prevalence of anogenital warts among participants in private health plans in the United States, 2003\u20132010: potential impact of human papillomavirus vaccination","volume":"103","author":"Flagg","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2023.02.049_b0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2105\/AJPH.2017.304119","article-title":"Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006\u20132014","volume":"108","author":"Flagg","year":"2018","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2023.02.049_b0050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/OLQ.0000000000000369","article-title":"Trends in male and female genital warts among adolescents in a safety-net health care system 2004\u20132013: correlation with introduction of female and male human papillomavirus vaccination","volume":"42","author":"Perkins","year":"2015","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2023.02.049_b0055","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2105\/AJPH.2016.303472","article-title":"Ecological association of human papillomavirus vaccination with cervical dysplasia prevalence in the United States, 2007\u20132014","volume":"106","author":"Flagg","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2023.02.049_b0060","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamaoncol.2016.3609","article-title":"Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era","volume":"3","author":"Benard","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0065","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/1055-9965.EPI-18-0885","article-title":"Trends in human papillomavirus vaccine types 16 and 18 in cervical precancers, 2008\u20132014","volume":"28","author":"McClung","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2023.02.049_b0070","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/cid\/ciy707","article-title":"Trends in high-grade cervical lesions and cervical cancer screening in 5 states, 2008\u20132015","volume":"68","author":"Gargano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.049_b0075","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer us preventive services task force recommendation statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.02.049_b0080","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.AOG.0000109426.82624.f8","article-title":"Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening","volume":"103","author":"Wright","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0085","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer","volume":"137","author":"Saslow","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0090","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1080\/03007995.2021.1932447","article-title":"Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States","volume":"37","author":"Prabhu","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vaccine.2023.02.049_b0095","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ygyno.2008.07.032","article-title":"Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan","volume":"111","author":"Insinga","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0100","unstructured":"NHIS - National Health Interview Survey n.d. https:\/\/www.cdc.gov\/nchs\/nhis\/index.htm (accessed October 13, 2022)."},{"key":"10.1016\/j.vaccine.2023.02.049_b0105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ygyno.2021.08.023","article-title":"Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013\u20132019","volume":"163","author":"Qin","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0110","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/jnci\/djab173","article-title":"Adherence to national guidelines on cervical screening: a population-based evaluation from a statewide registry","volume":"114","author":"Castle","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2023.02.049_b0115","doi-asserted-by":"crossref","unstructured":"Gargano JW, McClung N, Lewis RM, Park IU, Whitney E, Castilho JL, et al. HPV type-specific trends in cervical precancers in the United States, 2008\u20132016. Int J Cancer. 2023;152(2):137\u201350. https:\/\/doi.org\/10.1002\/ijc.34231.","DOI":"10.1002\/ijc.34231"},{"key":"10.1016\/j.vaccine.2023.02.049_b0120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2021.06.029","article-title":"Uptake of co-testing with HPV and cytology for cervical screening: a population-based evaluation in the United States","volume":"162","author":"Cuzick","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0125","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/OLQ.0000000000001379","article-title":"The estimated lifetime medical cost of diseases attributable to human papillomavirus infections acquired in 2018","volume":"48","author":"Chesson","year":"2021","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2023.02.049_b0130","unstructured":"How many cancers are linked with HPV each year? | CDC n.d. https:\/\/www.cdc.gov\/cancer\/hpv\/statistics\/cases.htm (accessed June 21, 2022)."},{"key":"10.1016\/j.vaccine.2023.02.049_b0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2023.02.049_b0140","doi-asserted-by":"crossref","unstructured":"Schabert VF, Ye X, Insinga RP, Singhal PK, Riedel AA. Five-year routine cervical cancer screening rates and intervals in a US health plan. Curr Med Res Opin. 2008;24:2429\u201335.","DOI":"10.1185\/03007990802281671"},{"key":"10.1016\/j.vaccine.2023.02.049_b0145","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/13696998.2021.1996958","article-title":"Phase-specific and lifetime economic burden of cervical cancer and endometrial cancer in a commercially insured United States population","volume":"24","author":"Shah","year":"2021","journal-title":"J Med Econ"},{"key":"10.1016\/j.vaccine.2023.02.049_b0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ygyno.2017.02.011","article-title":"Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas","volume":"145","author":"Lairson","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000472","article-title":"Cervical, vaginal, and vulvar cancer costs incurred by the medicaid program in publicly insured patients in Texas","volume":"23","author":"Fu","year":"2019","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.vaccine.2023.02.049_b0160","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ygyno.2017.12.019","article-title":"Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas","volume":"148","author":"Fu","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.oraloncology.2019.06.033","article-title":"Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas","volume":"96","author":"Zhao","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0170","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1055-9965.EPI-17-0220","article-title":"Medical care cost of oropharyngeal cancer among Texas patients","volume":"26","author":"Lairson","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2023.02.049_b0175","first-page":"1156","article-title":"Health care costs of anal cancer in a commercially insured population in the United States","volume":"24","author":"Wu","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.vaccine.2023.02.049_b0180","first-page":"294.e17","article-title":"Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States","volume":"37","author":"Lairson","year":"2019","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.vaccine.2023.02.049_b0185","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/lary.28139","article-title":"Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients","volume":"130","author":"Tam","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1016\/j.vaccine.2023.02.049_b0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajog.2004.01.042","article-title":"The health care costs of cervical human papillomavirus\u2013related disease","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0195","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1185\/03007990903136378","article-title":"Assessing incidence and economic burden of genital warts with data from a US commercially insured population","volume":"25","author":"Hoy","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vaccine.2023.02.049_b0200","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.049_b0205","doi-asserted-by":"crossref","unstructured":"Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007:1\u201324. https:\/\/stacks.cdc.gov\/view\/cdc\/6822 (accessed July 28, 2022).","DOI":"10.1037\/e601292007-001"},{"key":"10.1016\/j.vaccine.2023.02.049_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104736","article-title":"Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI","volume":"108","author":"Kreimer","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.vaccine.2023.02.049_b0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7326\/M19-1182","article-title":"Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States","volume":"172","author":"Laprise","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2023.02.049_b0220","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1080\/21645515.2019.1603562","article-title":"Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States","volume":"15","author":"Chesson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.02.049_b0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-3-030-03502-0_7","article-title":"HPV-associated anal cancer in the HIV\/AIDS patient","volume":"177","author":"Wang","year":"2019","journal-title":"Cancer Treat Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:41Z","timestamp":1759404341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23001846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":45,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23001846"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}